Should you hold ExOne (Xone) stock?
The consensus among Wall Street research analysts is that investors should "hold" ExOne stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XONE, but not buy additional shares or sell existing shares. View analyst ratings for ExOne or view top-rated stocks.
What is the ticker symbol for ExOne?
ExOne trades on the NASDAQ under the ticker symbol "XONE." Who are ExOne's major shareholders? ExOne's stock is owned by a variety of retail and institutional investors.
How much of ExOne's stock is owned by institutions?
47.99% of the stock of ExOne is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Earnings for ExOne are expected to grow in the coming year, from ($0.88) to ($0.64) per share.
What is the ExOne co?
What You Should Know The ExOne Co. engages in the development, manufacture, and marketing of three-dimensional (3D) printing machines. It offers 3D printing solutions to industrial customers in the aerospace, automotive, heavy equipment, energy, and oil and gas industries.
See more
Is ExOne stock a buy?
Of course, it did earn revenue of $11.10 million in the second fiscal quarter of 2020 for a total of about $50 million in annual sales. This means that it's trading for over 21x its trailing sales and that keeps some analysts from rating it a Buy.
What happen to Xone?
(NYSE: DM) ("Desktop Metal") today announced it has successfully completed its acquisition of The ExOne Company (NASDAQ: XONE) ("ExOne") following approval by a majority of ExOne's shareholders. The acquisition reinforces Desktop Metal's leadership in additive manufacturing (AM) for mass production.
Will Xone stock go up?
Based on our forecasts, a long-term increase is expected, the "XONE" stock price prognosis for 2027-07-16 is 31.504 USD. With a 5-year investment, the revenue is expected to be around +8414.65%. Your current $100 investment may be up to $8514.65 in 2027.
How much XONE stock?
One share of XONE stock can currently be purchased for approximately $26.70.
Who bought Xone?
Total transaction valued at $561.3 million. Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community. Desktop Metal, Inc. (NYSE: DM) has successfully completed its acquisition of The ExOne Company (NASDAQ: XONE) following approval by a majority of ExOne's shareholders.
Why is Xone 92?
The industry-standard Xone:92 is a versatile six channel analogue mixer, renowned for its expansive, involving sound. With its solid construction and easy to use interface, the 92 is on the riders of most of the world's top DJs and is a permanent fixture in the booth at many of the biggest superclubs.
How do you use Xone 92 filters?
0:092:57Xone 92 Filters Demo - YouTubeYouTubeStart of suggested clipEnd of suggested clip아 아 아 아 아 아 er 5 the icon 5 아 co 5 cool cool cool 5 o co we 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5.More아 아 아 아 아 아 er 5 the icon 5 아 co 5 cool cool cool 5 o co we 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5.
Should I buy or sell ExOne stock right now?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ExOne in the last twelve months. There are currently 2 hold ratings for th...
What is ExOne's stock price forecast for 2022?
2 equities research analysts have issued 12-month price targets for ExOne's stock. Their forecasts range from $25.50 to $25.50. On average, they ex...
How were ExOne's earnings last quarter?
The ExOne Company (NASDAQ:XONE) posted its quarterly earnings results on Tuesday, August, 10th. The industrial products company reported ($0.25) EP...
Who are ExOne's key executives?
ExOne's management team includes the following people: John F. Hartner , Chief Executive Officer & Director Douglas D. Zemba , Chief Financial O...
Who are some of ExOne's key competitors?
Some companies that are related to ExOne include Illinois Tool Works (ITW) , Parker-Hannifin (PH) , Ingersoll Rand (IR) , Dover (DOV) , Stanle...
What other stocks do shareholders of ExOne own?
Based on aggregate information from My MarketBeat watchlists, some companies that other ExOne investors own include 3D Systems (DDD) , Stratasys...
What is ExOne's stock symbol?
ExOne trades on the NASDAQ under the ticker symbol "XONE."
What is ExOne's stock price today?
One share of XONE stock can currently be purchased for approximately $26.70.
How much money does ExOne make?
ExOne (NASDAQ:XONE) has a market capitalization of $593.22 million and generates $59.25 million in revenue each year. The industrial products compa...
Barchart Technical Opinion
Business Summary
The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.
How much oil will be released from the Strategic Petroleum Reserve?
The ExOne Company provides three-dimensional printing machines and printed products to industrial customers. The Company also supplies the associated products, including consumables and replacement parts, and services including training and technical support. It manufactures and sells 3D printing machines...
Is oil a boon for Exxon?
The Energy Department will release 50 million barrels of oil from the Strategic Petroleum Reserve as part of efforts to lower gasoline prices.
ExOne (NASDAQ:XONE) Price Target and Consensus Rating
The positive trajectory in oil price is a boon for ExxonMobil's (XOM) upstream operations.
Analyst Price Target Consensus
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Ratings By Month
Sign-up to receive the latest news and ratings for XONE and its competitors with MarketBeat's FREE daily newsletter.
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
ExOne (NASDAQ:XONE) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
When will Xenon report results for 2021?
According to the issued ratings of 4 analysts in the last year, the consensus rating for ExOne stock is Hold based on the current 4 hold ratings for XONE. The average twelve-month price target for ExOne is $24.67 with a high price target of $25.50 and a low price target of $23.00. Learn more on XONE's analyst rating history
What is Xenon Pharmaceuticals?
(Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, November 10, 2021. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) on Wednesday, November 10, 2021 to discuss the third quarter 2021 financia
When is the Xenon webinar 2021?
BURNABY, British Columbia, April 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company , today announced that members of its executive management team will present a corporate overview and participate in the following virtual investor conferences: 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 10:15 am ET. The live webcast of the fireside chat can be accessed here.2021 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 3:00 pm ET. The live webcast of the company presentation can be accessed here. Details on company presentations and the links to webcasts can be found on the “Investors” section of Xenon’s website at http://investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event for 30 days. The above listed dates and times are subject to change. About Xenon Pharmaceuticals Inc. We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com. “Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner. Investor/Media Contact:Jodi RegtsXenon Pharmaceuticals Inc.Phone: 604.484.3353Email: [email protected]
What time is the Xenon conference call?
Webinar to be broadcast live on Monday, July 12, 2021 beginning at 10 am ETBURNABY, British Columbia, July 07, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today provided an update on its ongoing XEN1101 Phase 2b “X-TOLE” clinical trial, announcing that randomization of 326 patients was completed in late June. Based on completion of patient randomization, Xenon anticipates topline results from the Phase 2b X-TOLE clinical trial
What is the conference ID number for Xenon?
Conference Call Information Xenon will host a conference call and live audio webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the first quarter results and provide a corporate update. The webcast will be broadcast live on the Investors section of the Xenon website.
When is Xenon's annual meeting?
To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 1496232 . About Xenon Pharmaceuticals Inc.
What was the net loss for the quarter ended March 31, 2021?
BURNABY, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, provided a corporate update following its 2021 Annual Meeting of Shareholders (the “Annual Meeting”) held today on June 3, 2021. Dr. Simon Pimstone, Executive Chair of Xenon’s Board of Directors stated, “We announced plans for a leadership transition earlier in the year, implemented a seamless succession plan, and effected these appointments at our
